Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How do you treat front line de novo HER2 positive metastatic breast cancer with brain metastases?
Related Questions
In a patient with hormone-positive early breast cancer who experienced a myocardial infarction (MI) while on aromatase inhibitors (AI), should tamoxifen be considered as an alternative treatment?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
What initial treatment would you offer a patient with metastatic triple negative breast cancer with somatic BRCA1/2 mutation, CPS <10?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
Is there benefit of cold-cap use while patient is on sacituzumab-govitecan?
In patients with advanced HR+, HER2- breast cancer who have progressed on first-line CDK 4/6i and ET and found to have ESR1 mutation, are you offering combination of abemaciclib and elacestrant in the 2nd line or SERD monotherapy?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
